Accord Healthcare, a London-based supplier of chemotherapies, is to receive a £50 million joint investment deal from the UK government. The funds will be used to expand its Fawdon drug manufacturing site in Newcastle upon Tyne, England.

With the funding, Accord will invest in new product lines for prostate cancer, injectables for the treatment of rheumatoid arthritis, gastroenterology indicators and medicines for adjunctive cancer therapies. The Fawdon Site is expected to be of value in the event of a future pandemic and the investment concurs with the UK’s aim to secure local supply chains for critical drugs whilst increasing overall health resilience.